Chandana Sreenivasa R, Conley Barbara A
Division of Hematology/Oncology, Michigan State University, Breslin Cancer Center 401, W. Greenlawn Avenue, Lansing, MI, USA.
Expert Rev Anticancer Ther. 2008 Apr;8(4):645-52. doi: 10.1586/14737140.8.4.645.
Salivary gland cancers are relatively rare and quite diverse. Current therapy relies on local ablation. There are few large clinical trials or randomized trials to guide treatment, especially for metastatic disease. This article reviews the epidemiology, staging, molecular characteristics, and treatment evidence for the most common types of salivary cancers and suggests potential future diagnostic and treatment directions. Progress in understanding the molecular and cell biology of salivary gland cancers may lead to the development of targeted therapies in these rare tumors. Multidisciplinary and multi-institutional collaborative studies are needed to help improve survival in salivary gland cancers.
涎腺癌相对罕见且种类繁多。目前的治疗依赖于局部消融。几乎没有大型临床试验或随机试验来指导治疗,尤其是针对转移性疾病的治疗。本文综述了最常见类型涎腺癌的流行病学、分期、分子特征和治疗证据,并提出了未来潜在的诊断和治疗方向。对涎腺癌分子和细胞生物学认识的进展可能会促使针对这些罕见肿瘤开发靶向治疗方法。需要开展多学科、多机构的协作研究来帮助提高涎腺癌患者的生存率。